New injection aims to suppress hepatitis b virus
NCT ID NCT07635186
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). Participants will receive multiple doses and be followed for 24 weeks after treatment ends.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AHB-137
What this could lead to
If successful, AHB-137 could offer a new treatment option that helps control chronic hepatitis B and reduces the risk of liver damage.
What could go wrong
This is an early-phase trial with a small number of participants. The drug may not work as expected or could cause side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China